Outcome MeasureOther

BPRS

Brief Psychiatric Rating Scale

5 Papers in Blossom

Clinical Thresholds

18126
Minimal symptoms
Score 18–30
Mild
Score 31–40
Moderate
Score 41–52
Severe
Score 53–126

Outcome Data Across Studies

Reported results for BPRS across 5 studies with quantitative data.

Outcome data across 15 study arm–timepoint observations
SD
The peak experience variable in DPT-assisted psychotherapy with cancer patients
1997Exploratory
DPT-assisted psychotherapy(experimental)0184.60.8—
The peak experience variable in DPT-assisted psychotherapy with cancer patients
1997Exploratory
DPT-assisted psychotherapy(experimental)0124.00.7—
Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression
2012Safety
Open-label ketamine phase(experimental)0244.00.1—
Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression
2012Safety
Open-label ketamine phase(experimental)0.027778244.50.9—
Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression
2016Secondary
Ketamine(experimental)03035.54.2—
Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression
2016Secondary
Ketamine + Propofol(experimental)03036.55.2—
Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression
2016Secondary
Propofol(active_comparator)03036.96.1—
Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression
2016Secondary
Ketamine(experimental)03025.6——
Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression
2016Secondary
Ketamine + Propofol(experimental)03026.6——
Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression
2016Secondary
Propofol(active_comparator)03027.3——

Papers Using BPRS

Paywallindividual

Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression

This open-label study (n=97) on patients with unipolar and bipolar depression examined the effects of six repeated ketamine infusions. Significant and sustained improvements in depression and suicidal ideation were observed, with response and remission rates at 68.0% and 50.5%, respectively. The treatment was effective and safe, demonstrating rapid antidepressant and antisuicidal effects. Positive response factors included early response, higher income, and no prior psychiatric hospitalization.

Published
Journal
Journal of Psychiatric Research
Authors
Zheng, W., Zhou, Y-L., Liu, W., Wang, C-Y., Zhan, Y., Chen, L., Ning, Y-P., Li, H., Li, M.
Open Accessindividual

Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial

This randomised study (n=80) found that participants with depression (MDD) and suicidal ideation (SSI/SI) who were treated with ketamine (IV, 35mg/70kg) have significantly lower SSI scores versus treatment with midazolam (another anesthetic). This effect consistently held up to 6 weeks later.

Published
Journal
American Journal of Psychiatry
Authors
Grunebaum, M. F., Galfalvy, H. C., Choo, T. H., Keilp, J. G., Moitra, V. K., Parris, M. S., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., Oquendo, M. A., Mann, J. J.
Paywallindividual

Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression

This randomised, double-blind, active placebo-controlled study (n=90) compared the antidepressant efficacy between ketamine (56mg/70kg), the anesthetic propofol (56mg/70kg), and the combination of ketamine (35mg/70kg) plus propofol (35mg/70kg), within the context of pretreatment for electroconvulsive therapy for patients with treatment-resistant depression (TRD). Compared to the others, the ketamine group exhibited earlier improvements in depression, better seizure parameters and seizure quality in electroconvulsive therapy, and a lower degree of executive cognitive impairment, which highlights the usefulness of ketamine-assisted electroconvulsive therapy for treating depression.

Published
Journal
Journal of Affective Disorders
Authors
Zhong, X., He, H., Zhang, C., Wang, Z., Jiang, M., Li, Q., Zhang, M., Huang, X.
Open Accessindividual

Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression

This open-label study (n=24) found that repeated infusions of ketamine can sustain the rapid anti-depressant effect obtained after one infusion. Nevertheless, the effect of 6 infusions was only maintained for a median of 18 days.

Published
Journal
Biological Psychiatry
Authors
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., Aan Het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., Iosifescu, D. V.
Open Accessindividual

The peak experience variable in DPT-assisted psychotherapy with cancer patients

This study (1977; n = 34) found that peak experiences may be an important factor in determining the efficacy of DPT-assisted psychotherapy for cancer patients.

Published
Journal
Journal of Psychedelic Drugs
Authors
Richards, W. A., Rhead, J. C., Dileo, F. B., Yensen, R.

Quick Facts

Full Name
Brief Psychiatric Rating Scale
Domain
Other
Papers Indexed
5
Score Range
18–126
Interpretation
Lower = better
Unit
points
All Measures